Amgen Announced At ESMO Saturday, Phase 3 DeLLphi-305 Data Showing IMDELLTRA + IMFINZI Reduced Death Risk By 58% In First-Line ES-SCLC Maintenance, With Median Overall Survival Of 21.1 Vs. 12.7 Months; One-Year Survival Of Nearly 80% Vs. 53%
Share
Why It Matters
Amgen's new medicine helped lung cancer patients live much longer. This shows the drug works well, which is good news for the company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.